Sorivudine

Research use only, not for human use.

Sorivudine has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus by interfering with viral DNA synthesis.

Sorivudine has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus by interfering with viral DNA synthesis.(In Vitro):Sorivudine is a pyrimidine nucleoside analog with in vitro inhibitory activity against varicella zoster virus (VZV) at concentrations of 0.0001-0.004 mg/ml. Sorivudine also inhibits HSV-I replication at concentrations ranging from 0.03-0.1 mg/ml. Sorivudine inhibited strains of HSV-1 and HSV-2 (wild-type strains VR-3 and UW-268) with ID50s of 0.39 and 0.67 μM, respectively.(In Vivo):Sorivudine (12.5 mg/kg) prolonged survival in treated mice. At doses above 50 mg/kg, mortality was significantly reduced. In the varicella virus infection model in African green monkeys (Cerophthecus aethiops), Sorivudine (20 mg/kg intramuscularly or 100 mg/kg orally daily) completely prevented viremia and death.

BV-araU

Cell Cycle/DNA Damage

DNA/RNA Synthesis

Analogue of amino acids

——

——

77181-69-2

349.1

C11H13BrN2O6

>98% (HPLC)

——

OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1cc(\C=C\Br)c(=O)[nH]c1=O

——

(-20℃)

With Ice Pack

≥ 2 years